180 related articles for article (PubMed ID: 38396351)
21. Targeted Therapy for Prostate Cancer by Prostate-Specific Membrane Antigen-Targeted Small-Molecule Drug Conjugates.
Nakajima R
Chem Pharm Bull (Tokyo); 2024; 72(2):136-142. PubMed ID: 38296554
[TBL] [Abstract][Full Text] [Related]
22. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
[TBL] [Abstract][Full Text] [Related]
23. Antibody drug conjugates beyond cytotoxic payloads.
Hobson AD
Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349
[TBL] [Abstract][Full Text] [Related]
24. Drug conjugate-based anticancer therapy - Current status and perspectives.
Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
[TBL] [Abstract][Full Text] [Related]
25. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
[TBL] [Abstract][Full Text] [Related]
26. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
McCombs JR; Owen SC
AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
[TBL] [Abstract][Full Text] [Related]
27. αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.
Dal Corso A; Pignataro L; Belvisi L; Gennari C
Curr Top Med Chem; 2016; 16(3):314-29. PubMed ID: 26126915
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
[TBL] [Abstract][Full Text] [Related]
29. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
Fatima SW; Khare SK
J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
[TBL] [Abstract][Full Text] [Related]
30. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy.
Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M
J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038
[TBL] [Abstract][Full Text] [Related]
31. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Cazzamalli S; Corso AD; Neri D
J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855
[TBL] [Abstract][Full Text] [Related]
32. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
33. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
[TBL] [Abstract][Full Text] [Related]
34. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates.
Schuster S; Juhász É; Halmos G; Neundorf I; Gennari C; Mező G
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563462
[TBL] [Abstract][Full Text] [Related]
35. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D
Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298
[No Abstract] [Full Text] [Related]
36. Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications.
Tamatam R; Mohammed A
Eur J Med Chem; 2024 Jun; 272():116441. PubMed ID: 38759455
[TBL] [Abstract][Full Text] [Related]
37. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
38. PSMA-targeted small-molecule docetaxel conjugate: Synthesis and preclinical evaluation.
Machulkin AE; Uspenskaya AA; Zyk NY; Nimenko EA; Ber AP; Petrov SA; Shafikov RR; Skvortsov DA; Smirnova GB; Borisova YA; Pokrovsky VS; Kolmogorov VS; Vaneev AN; Ivanenkov YA; Khudyakov AD; Kovalev SV; Erofeev AS; Gorelkin PV; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
Eur J Med Chem; 2022 Jan; 227():113936. PubMed ID: 34717125
[TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
40. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Zhou L; Lu Y; Liu W; Wang S; Wang L; Zheng P; Zi G; Liu H; Liu W; Wei S
Exp Hematol Oncol; 2024 Mar; 13(1):26. PubMed ID: 38429828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
